Allosteros Therapeutics, Inc. is a drug discovery company targeting unique sites on key proteins in cardiovascular disease signaling pathways. Howard Schulman, PhD and Mark Anderson, MD, PhD, founded Allosteros in 2009 in Palo Alto, California. Howard Schulman leads the company’s drug development efforts as President & CSO, and Mark Anderson acts as an advisor to the company.

< Back to Portfolio